| ID | 1066 |
| Name of the vaccine | Infanrix-IPV+Hib |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | Over 2 months |
| Description of the vaccine | Diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed). |
| Name of the manufacturer | GlaxoSmithKline Biologicals S.A |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2005 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | NA |
| Vaccine formulation | Powder and suspension |
| Dosage | Two or three injections, gap of 1 month. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunisation against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b disease. |
| Export | Marketing authorisation holder - SmithKline Beecham Ltd |
| Approval | Member States of the EEA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For Diphtheria, haemophilus influenzae type b, pertussis and poliomyelitis. |
| Side effects of vaccine | Loss of appetite, high temperature, swelling, pain and redness, feeling restless, diarrhoea, hard lump, large swelling. |
| Post vaccination | NA |
| Dose type | Combination (2 or 3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01309646 |
| Reference | https://www.medicines.org.uk/emc/files/pil.5301.pdf |
| Other name | NA |
| Additional Links | https://www.medicines.org.uk/emc/medicine/28678#gref
|